ACHR three-lens brief
Evidence-based stock research on ACHR. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Trading at 11% of its 52-week range — deep in the lower band.
- Trading at 11% of its 52-week range — deep in the lower band.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Outperforming SPY by 17.8pp over 30 days.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Analyst mean target $10.61 — 95% above current (9 analysts).
ACHR closed at $5.45 (-0.91%) as of 2026-09-11. Market cap: $4.20B. Price is below the 50-day MA and below the 200-day MA. Positives: outperforming SPY by 17.8pp over 30 days.; analyst mean target $10.61 — 95% above current (9 analysts).. Concerns: trading at 11% of its 52-week range — deep in the lower band.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $5.00M, net income -$263.20M, free cash flow -$376.44M.
Why three lenses on ACHR, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ACHRacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/ACHR" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ACHR brief"></iframe>